June 11, 2025 03:39 PM EDT

Federal officials schedule three listening sessions this summer to address drug competition

Max Bayer

Pharma Reporter

The Federal Trade Commission and Department of Justice plan to have three listening sessions focused on how to lower drug prices through enhanced market competition …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Federal officials schedule three listening sessions this summer to address drug competition

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Another round of consolidation is coming, FDA commissioner tells staff

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices

Fed­er­al of­fi­cials sched­ule three lis­ten­ing ses­sions this sum­mer to ad­dress drug com­pe­ti­tion

Max Bayer

Pharma Reporter

Sign up to read this article for free.

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

Federal officials schedule three listening sessions this summer to address drug competition

Another round of consolidation is coming, FDA commissioner tells staff

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices